id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1873352,59c67d5f-2758-4630-859e-d3cbbb2897fa,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2016,third_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,128875,0,0,2016-10-06T10:09:33.290000-04:00
1873519,5893ed93-4ec5-40d7-8f93-c9c4b850a0ec,Q3,NELSON MULLINS RILEY & SCARBOROUGH,285871,CASCADE HEMOPHILIA CONSORTIUM,2016,third_quarter,PHA,Issues related to 340B Drug Pricing Progam,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-10-06T13:47:33.257000-04:00
1873521,3d846365-f6cc-4f66-bc28-653f5aa39c72,Q3,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2016,third_quarter,PHA,"Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-10-06T13:48:34.693000-04:00
1873600,98ad3ed9-a90f-42d7-b675-ef726476488a,Q3,AMERICAN COLLEGE OF EMERGENCY PHYSICIANS,1967,AMERICAN COLLEGE OF EMERGENCY PHYSICIANS,2016,third_quarter,PHA,"H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act

S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015","HOUSE OF REPRESENTATIVES,SENATE",,512329,0,0,2016-10-06T22:34:59.390000-04:00
1873715,e8b7173c-d16a-4ed0-8b6a-68b3bdbc6edc,Q3,WAXMAN STRATEGIES,401103693,340B HEALTH,2016,third_quarter,PHA,Laws and regulations affecting the 340B Drug Discount Program,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),White House Office",18750,,0,0,2016-10-07T11:38:35.293000-04:00
1873731,881551d5-98bf-43cc-96d2-5f8ecf036978,Q3,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2016,third_quarter,PHA,In-office compounding; outsourcing facilities; Drug Quality and Security Act,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",,,0,0,2016-10-07T11:44:47.280000-04:00
1873810,773d1682-449e-48fe-9833-9a96d158791e,Q3,NELSON MULLINS RILEY & SCARBOROUGH,285871,"INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.)",2016,third_quarter,PHA,Any legislation and regulation to the treatment of opioid abuse.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-10-07T14:06:54.913000-04:00
1873923,26bcdfbc-a317-4567-9c81-c36f272d5ddf,Q3,AMERICAN AMBULANCE ASSOCIATION,56018,AMERICAN AMBULANCE ASSOCIATION,2016,third_quarter,PHA,"Lobbied in support of the Protecting Patient Access to Emergency Medications Act (H.R. 4365, S. 2932) to ensure the continuity of standing orders for the administration of certain controlled substances by paramedics and EMTs to patients.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,300000,0,0,2016-10-07T16:12:35.500000-04:00
1874040,0b7a72b9-1df4-43a6-8783-d6e6e269163c,Q3,"PARRY, ROMANI, DECONCINI & SYMMS",30792,ROCK & ASSOCIATES,2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",18000,,0,0,2016-10-08T12:18:07.800000-04:00
1874108,7ab117e6-ff04-45fe-a9f8-9571f6ba53e6,Q3,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2016,third_quarter,PHA,"H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas.
H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas.
S.524 Comprehensive Addiction and Recovery Act of 2016. IPC is against as currently written.
Actual Acquisition Cost (AAC) adoption with state Medicaid programs.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2016-10-09T16:24:39.720000-04:00
1874151,d14a4b85-7364-45b2-a6c2-d841a2a78833,3T,HANCE SCARBOROUGH,17443,ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS,2016,third_quarter,PHA,"Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs.","HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2016-10-10T10:36:39.560000-04:00
1874571,f70c170c-b906-4f17-bcf7-c2a5ed953865,Q3,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-10-11T02:47:12.383000-04:00
1874575,b140c0d8-9c02-4ef4-b7e3-5d96d56b26d2,Q3,ROCK & ASSOCIATES,33545,DIAMONDBACK DRUGS,2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-10-11T02:52:15.133000-04:00
1874581,706ed458-7389-4d3c-8a59-042e0dfb301b,Q3,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-10-11T02:55:16.760000-04:00
1874584,514f70c4-e51e-44d1-8570-a270592984f0,Q3,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-10-11T02:57:18.263000-04:00
1874589,3af5d910-68a9-47f0-8496-0591913141a9,Q3,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-10-11T02:59:19.700000-04:00
1874592,a2f0bc62-a7ae-4509-b770-4a8b8c8df3ab,Q3,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2016,third_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-10-11T03:01:21.200000-04:00
1874637,b3042ccb-6dce-4b3b-85f0-3a9d11648ad6,Q3,MR. BRIAN KELLY,40024191,LUNDBECK PHARMACEUTICALS,2016,third_quarter,PHA,FDA Reform,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2016-10-11T10:08:06.227000-04:00
1874774,e2452ed8-6415-42c3-a264-2de027e4926a,Q3,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2016,third_quarter,PHA,"Any language supporting the expanded use of virtual care/telemedicine, including HR 2799 supporting changes in definitions to expand the use of telemedicine.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,28557,0,0,2016-10-11T11:52:30.400000-04:00
1875019,3b2ae95c-54cb-4650-bf8e-c22ff2e3531d,Q3,HOLLAND & KNIGHT LLP,18466,PROTECTING ACCESS TO PAIN RELIEF COALITION,2016,third_quarter,PHA,Advocating for policy to ensure patient access to pain relief.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-11T15:19:17.800000-04:00
1875028,cc96cfb9-b0e7-42e5-81e3-1d2c584170c5,Q3,HOLLAND & KNIGHT LLP,18466,THE BIOSIMILARS FORUM,2016,third_quarter,PHA,"Medicare reimbursement issues, FDA regulation of biosimilars.","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2016-10-11T15:25:21.837000-04:00
1875088,475547b7-75cd-4d23-8f31-f7cbefbcdbef,Q3,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2016,third_quarter,PHA,"Reimbursement of Pharmacist Services (HR592, S314)
Transitions of Care
Risk Evaluation and Mitigation Services
Track and Trace/Supply Chain
Health Information Technology
Immunizations
Compounding
Tele-medicine
Quality Rating
AMP FULs/MAC Pricing
Biosimiliars/Biologic Products (S 2700)
Drug Importation
Generics Labeling
Pharmacy Benefit Managers
Preferred Pharmacy Network (HR793)
Electronic Labeling
21st Century Cures (HR6, HR 350)
Drug Disposal/Management
Drug Prices
Direct and Indirect Remuneration Fees (HR 5951, S 3308)
Cody Miller Act (S 2214)
Lab Developed Tests","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,30000,0,0,2016-10-11T16:31:18.867000-04:00
1875204,132c7d00-998a-4dc4-a133-2395f3511263,Q3,"CONNECT 4 STRATEGIES, LLC",401103720,BIOMARIN PHARMACEUTICAL INC.,2016,third_quarter,PHA,"Rare pediatric review voucher.
S 1878 and HR 1537","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-10-11T20:49:32.220000-04:00
1875257,ab5ea350-583a-468b-86bc-e0d96f47b291,Q3,"UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY",401097063,"UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY",2016,third_quarter,PHA,--340B Program Mega Guidance,"Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,6695,0,0,2016-10-12T10:08:05.457000-04:00
1875549,cbc0dff1-e931-4125-a78f-e2f7cc7ed9f2,Q3,"ARNALL GOLDEN GREGORY, LLP",400713137,PHARMA AND BIOPHARMA OUTSOURCING ASSOCIATION,2016,third_quarter,PHA,FDA issues; Generic Drug Free User Act issues; small business relief legislation,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-10-12T14:00:01.390000-04:00
1875612,084fd17f-132e-4b9a-a5b8-a8d931f23d21,3A,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2016,third_quarter,PHA,"Reimbursement of Pharmacist Services - HR592/S314
Transitions of Care
Risk Evaluation and Mitigation Services
Track and Trace/Supply cChain
Health Information Technology
Immunizations
Compounding
Tele-Medicine
Quality Rating
AMP FULs/MAC P ricing
Biosimiliars/Biologic Products (S 2700)
Drug Importation
Generics Labeling
Pharmacy Benefit Managers
Preferred Pharmacy Network (HR793)
Electronic Labeling
21st Century Cures/Innovation Bills (HR6, HR 350)
Drug Disposal/Management
Drug Prices
Direct and Indirect Remuneration Fees (HR 5951, S3308)
Lab Developed Tests","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,30000,0,0,2016-10-12T14:25:28.557000-04:00
1875800,db2b65a4-3471-421e-9a97-44d731b5c9e2,3A,VAN FLEET ASSOCIATES,39781,INNOVATIVE BIODEFENSE,2016,third_quarter,PHA,Counter FDA warning letter.,Food & Drug Administration (FDA),,,0,0,2016-10-12T15:42:49.753000-04:00
1876254,47719359-13ab-475b-a9a6-1ab03b1241c1,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,"CARDINAL HEALTH, INC.",2016,third_quarter,PHA,"Issues related to prescription drug abuse.
Issues related to pharmaceutical market value.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-13T10:19:06.483000-04:00
1876274,b793e62a-7dbc-47ad-b6b5-ffca18179544,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2016,third_quarter,PHA,"Issues related to pharmaceutical market value.
Issues related to prescription drug abuse.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-13T10:30:26.420000-04:00
1876592,006739fb-fcbe-42d3-99dd-5111cb858e36,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2016,third_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-10-13T13:00:32.527000-04:00
1876683,711172e2-d0bf-4ed9-9b7a-3929baea9596,Q3,"MERCURY PUBLIC AFFAIRS, LLC",70175,KALISPELL REGIONAL HEALTHCARE,2016,third_quarter,PHA,Veteran pharmacy issues and polices,"Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2016-10-13T13:48:36.973000-04:00
1876703,8223d458-cc2e-4603-8fdd-7b2c240a94ba,Q3,"KENT & O'CONNOR, INC.",21426,INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION,2016,third_quarter,PHA,Legislation and regulations relating to drug and safety issues.,"Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection",20000,,0,0,2016-10-13T13:55:50.747000-04:00
1876846,6ac47e33-a342-4250-b943-7fe8413199bd,Q3,KATE MOSS,25988,CVS HEALTH,2016,third_quarter,PHA,Issues related to prescription drug abuse and drug supply chain safety.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-10-13T15:15:38.770000-04:00
1876970,1e87a48d-77a7-4ccc-9f48-fd31f75a9701,Q3,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2016,third_quarter,PHA,"Pseudoephedrine

Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number).

Extended Producer Responsibility/Pharmaceutical Stewardship (Drug Take-Back)

H.R. 4931 - Pharmaceutical Stewardship Act of 2016. Requires the Drug Enforcement Administration to establish and implement a national pharmaceutical stewardship program to collect and dispose of prescription medications; all sections.

H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 (COARA). Amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize the Attorney General to make grants to assist State and local governments in addressing the national epidemic of opioid abuse, and for other purposes (all sections).

S. 524 - Comprehensive Addiction and Recovery Act of 2016 (CARA; became P.L. 114-198 on 7/22/2016).  Authorizes the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes (Section 201 - expands eligible uses of grant funds to include drug take-back efforts; Section 203 requires coordination among multiple government agencies to develop a prescription drug take-back program).

Oral Contraceptives

H.R. 5138 - Over-the-Counter Contraceptives Act of 2016. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections.

S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections.

H.R. 3163/S. 1532 - Affordability is Access Act.  Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections.

Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",,290000,0,0,2016-10-13T16:13:55.930000-04:00
1876980,29cde65d-9b23-4781-b997-ff2677fc9738,Q3,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,35968,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2016,third_quarter,PHA,Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding.,"Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE,Veterans Affairs, Dept of (VA)",,70000,0,0,2016-10-13T16:24:03.787000-04:00
1877009,833f1032-a9c9-4aea-93d7-c54d7b63be73,Q3,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2016,third_quarter,PHA,"Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care.  Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records.","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,168000,0,0,2016-10-13T17:00:32.367000-04:00
1877170,60b6a3c7-9192-4b38-b5cf-0a6132a1dd3a,Q3,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2016,third_quarter,PHA,"H.R. 244 - MAC Transparency Act of 2015; 
Congressional Oversight of 340 B Program;
S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act;
Issues related to FDA implementation of The Drug Quality and Security Act related to compounding;
Issues Related to Direct and Indirect Renumeration (DIR) Fees;
H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE",,335000,0,0,2016-10-14T09:26:17.153000-04:00
1877541,510fe923-8f5c-4e5e-9e28-8ddb2f22b05d,Q3,JOHNS HOPKINS UNIVERSITY,20664,JOHNS HOPKINS UNIVERSITY,2016,third_quarter,PHA,Pharmaceutical drug prices,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,100000,0,0,2016-10-14T12:30:31.617000-04:00
1878931,faa59872-596c-425f-8baf-54b91ce75d15,Q3,"MEHLMAN CONSULTING, INC.",284950,THE CAMPAIGN FOR SUSTAINABLE RX PRICING,2016,third_quarter,PHA,"Issues related to transparency and competition in the prescription drug market.
S.3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES).
S. 3335,  Fair Accountability and Innovative Research Drug Pricing Act of 2016 (FAIR).
Food and Drug Administration Appropriations Act.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2016-10-17T11:32:41.330000-04:00
1878997,5eacbcd9-8701-4d15-9e5c-fd320d4d9c63,Q3,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",4653,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",2016,third_quarter,PHA,"Proposals relating to the regulation of direct to consumer prescription drug advertising 
H.R. 4565, Responsibility in Drug Advertising Act of 2016, to prohibit for three years after FDA approval direct to consumer prescription drug advertising","Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE",,420000,0,0,2016-10-17T11:41:18.197000-04:00
1879019,c3c38c65-790f-43de-8a5a-861e5042b20c,Q3,"MEHLMAN CONSULTING, INC.",284950,WALMART INC,2016,third_quarter,PHA,Implementation of Medicare Part D and the Affordable Care Act.,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2016-10-17T11:43:27.557000-04:00
1879022,9274968e-383d-499e-b926-02c44bf1bded,Q3,"MEHLMAN CONSULTING, INC.",284950,VIRTUS PHARMACEUTICALS LLC,2016,third_quarter,PHA,Generic Drugs.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-17T11:45:30.170000-04:00
1879066,db20de44-8b17-43e1-a847-d3bb833bea68,3T,"WILLIAMS AND JENSEN, PLLC",41454,FAGRON NORTH AMERICA,2016,third_quarter,PHA,Issues related to Drug Quality and Security Act (DQSA) and pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2016-10-17T11:58:49.540000-04:00
1879349,ab3f09f7-8c56-4a9c-a7a9-26521009326d,Q3,CHAMBER HILL STRATEGIES,400645947,AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL),2016,third_quarter,PHA,"Implementation issues related to P.L. 113-54, the Drug Quality and Security Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-17T13:38:47.083000-04:00
1879409,30642ddd-8c4b-476c-8a44-e7dc21e44e1a,Q3,WALTER CONSULTING,301697,AMERISOURCEBERGEN CORPORATION,2016,third_quarter,PHA,"H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015
S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-10-17T13:52:19.127000-04:00
1879614,3435f6f1-249c-48a7-a1fb-e7ee660b8b4b,Q3,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2016,third_quarter,PHA,"H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid funding and other prescription drug related issues. 

National Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. 

The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.  

The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders.  Particular focus on formulary policies. 

Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.

Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.

Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs.

Issues related to the pricing of prescription medications.

Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. 

Issues related to the treatment of pharmacy benefit managers in federal programs. 

Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. 

Issues related to access and affordability for prescription medications for both government and private sector benefit programs.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-17T14:26:54.313000-04:00
1879669,04a6d35d-4b18-4e77-8510-2369473e5b70,Q3,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2016,third_quarter,PHA,"H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies. 

The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.

H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits. 
  

The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders.  Particular focus on formulary policies. 

H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency  for prescription drugs that exist under current law and regulatory policies. 

Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.

Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.

Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.

Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. 

Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. 

Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-17T14:37:31.120000-04:00
1879780,7996fd7d-2c67-4694-b644-9ce7bcc568bf,Q3,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2016,third_quarter,PHA,"H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues, policies focused on antibiotic resistance and other public health related policies. 

S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States.  Work focused on the inclusion of ""lock in"" programs in the Medicare program to prevent and protect seniors from opioid addiction.  

S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public.

S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program. 

H.R. 5054 - Agriculture Appropriations Bill for FY 2017 - Issues related to FDA treatment of antibiotics and compounding of certain pharmaceuticals. 
 
Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC. 

Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget. 

Supporting policies to maintain the integrity of laws regarding compounding of certain medications.

Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-17T14:54:37.977000-04:00
1879898,68fbbb48-6d7a-4d9a-b74e-f0b9140edbd2,Q3,NORIDIAN MUTUAL INSURANCE COMPANY,6473,NORIDIAN MUTUAL INSURANCE COMPANY,2016,third_quarter,PHA,"Opioid Education, Pharmaceutical cost containment","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-10-17T15:16:47.467000-04:00
1879976,3a085c09-85ae-4140-a5a6-6f51f429797d,Q3,ACG ADVOCACY,2057,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2016,third_quarter,PHA,"Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues.  
Advocating for coverage of pharmacists services under Medicare Part B.  
Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication.  
Advocating for fair and accurate Medicaid pharmacy reimbursement.  
Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management.
Issues related to pharmacy reimbursement for 21st Century Cures.
Issues regarding TriCare coverage for pharmacies.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-17T15:30:33.463000-04:00
1880119,c8eb482b-233f-48ad-9385-e2f9e05ee3bc,Q3,"EXPRESS SCRIPTS, INC.",294416,"EXPRESS SCRIPTS, INC.",2016,third_quarter,PHA,"Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office",,690000,0,0,2016-10-17T16:02:20.507000-04:00
1880265,9bd6644a-92cd-466c-b8e0-b2f6556bd882,Q3,MR. GALEN RESER,401055978,PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS),2016,third_quarter,PHA,"Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, ""Restoring Access to Medication Act of 2015,"" H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. ""Fairness to Pet Owners Act of 2015,"" S.1200.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-10-17T16:19:38.427000-04:00
1880356,31e08d6c-cfed-47ab-bae3-acdc6f190e78,Q3,"MEHLMAN CONSULTING, INC.",284950,ASCENSION HEALTH ALLIANCE,2016,third_quarter,PHA,"Prescription Drugs
Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES)
FAIR Drug Pricing Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-10-17T16:39:30.227000-04:00
1880700,ed881810-8108-4d57-b6b7-f2b8912605ce,Q3,EMPIRE CONSULTING GROUP,400703105,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2016,third_quarter,PHA,Issues relating to Medicare Parts D and D; prescription drug costs/pricing; legislation and issues relating to opioids; budget.,HOUSE OF REPRESENTATIVES,40000,,0,0,2016-10-17T21:33:54.513000-04:00
1880821,b9e10b6e-11f5-4206-9151-a820748b5665,Q3,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2016,third_quarter,PHA,"Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price ""gag clauses""; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting ""any willing pharmacy"" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment, oppose use of savings from home infusion payment reform for purposes other than creating a Medicare home infusion benefit; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913)- support  (with some concerns about pharmacy lock-in policy); submitted comments on Management Standards for Hazardous Waste Pharmaceuticals (EPA-HQ-RCRA-2007-0932); meeting with DEA on Controlled Substances Act (21 USC 802); proposed changes to regulation of Laboratory Developed Tests (FDA-2011-D-0360-Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests) - oppose; Comprehensive Addiction and Recovery Act of 2016 ((S.524), monitoring for pharmacy lock-in policy, which includes exemption for LTC) - support; Increasing Competition in Pharmaceuticals Act (S.2615/H.R.4784) - support; CREATES Act addressing REMS abuses (S.3056) - support.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",,410000,0,0,2016-10-18T08:58:40.667000-04:00
1881033,6a312c8d-010f-4ca4-8301-453b2eed09a4,Q3,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2016,third_quarter,PHA,"General Pharmacy Issues (HR6/2713); opioid abuse (S524, HR953, HR2805, HR4499); specialty drug pricing","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2016-10-18T10:12:56.763000-04:00
1881104,cae75a8d-5a66-48d5-bc7b-b9404e9db24c,Q3,RED+BLUE STRATEGIES,400693064,BLUE CROSS BLUE SHIELD OF MASSACHUSETTS,2016,third_quarter,PHA,"H.R. 5327 - Continuing Appropriatins and Military Construction, VA and Related Agencies Appropriations Act of 2017 and Zika Response and Preparedness Act.  Issues regarding the funding of opioid related programs. 

S. 524 - the Comprehensive Addition and Recovery Act- issues related to ensuring best prescribing practices for opioids in the country and solutions developed by BCBSMA to combat abuse.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-18T10:24:51.070000-04:00
1881168,755b268c-7ecc-4fc1-9ea1-df7343f7a1c0,Q3,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2016,third_quarter,PHA,"H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.

Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-18T10:34:19.890000-04:00
1881350,f71f42e0-c671-47a5-a9ec-459d6b248190,Q3,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),400265214,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),2016,third_quarter,PHA,Issues related to pharmaceutical pricing and federal oversight by the FDA,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,198000,0,0,2016-10-18T10:59:57.647000-04:00
1881593,8a9c20db-1179-41e2-bd6e-4d3b258b5c20,Q3,TODD STRATEGY GROUP,401103321,BIOTECHNOLOGY INNOVATION ORGANIZATION,2016,third_quarter,PHA,Drug Pricing and Access.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-18T11:33:09.410000-04:00
1881604,cad95db9-c2de-435e-95f4-926d02e11f91,Q3,TODD STRATEGY GROUP,401103321,CELGENE CORPORATION,2016,third_quarter,PHA,S.3056 - CREATES Act of 2016.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-10-18T11:35:16.633000-04:00
1881716,373a9c2d-ad05-4992-88a1-281f3cd09cd4,Q3,SAFEWAY INC.,300173,SAFEWAY,2016,third_quarter,PHA,"H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act, all provisions.  H.R. 4909, FY 2017 National Defense Authorization Act, provisions related to TRICARE and pharmacy access.  H.R. 953/S. 524, Comprehensive Addition and Recovery Act, provisions related to state prescription drug monitoring programs.  H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, all provisions. H.R. 3250, DXM Abuse Prevention Act, provisions related to retail pharmacy.","HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2016-10-18T11:53:16.210000-04:00
1881790,154908f0-94cb-44a4-bd02-fd0ded9da77b,Q3,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2016,third_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2016-10-18T12:01:55.530000-04:00
1881804,9c27e79a-87d3-4515-979a-70a1cadee1a7,Q3,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2016,third_quarter,PHA,"HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2016-10-18T12:05:03.580000-04:00
1881807,cd1f1672-61fa-4558-ac49-a5a11f1cc54d,Q3,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2016,third_quarter,PHA,issues related to the 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-18T12:05:06.173000-04:00
1881826,702e2f60-a412-4860-958c-6ad7f97e03c3,Q3,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2016,third_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",50000,,0,0,2016-10-18T12:06:14.973000-04:00
1881947,4d60f017-1cd2-4d3d-89fd-4b7f05eef1b2,Q3,THORN RUN PARTNERS,400534596,"EXPRESS SCRIPTS, INC.",2016,third_quarter,PHA,"H.R.244, MAC Transparency Act; pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. S.2943/H.R.4909, National Defense Authorization Act for Fiscal Year 2017; provision authorizing a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-18T12:28:31.257000-04:00
1882059,0cad3c00-4fc4-4d59-ac93-712b8d26baab,Q3,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2016,third_quarter,PHA,Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-10-18T12:48:37.877000-04:00
1882136,11325f1e-90e6-426a-97a8-1d7c6a6af5fc,Q3,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2016,third_quarter,PHA,"Prescription Drug Pricing - no specific bill
Direct to Consumer Advertising - no specific bill
Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA)",,50000,0,0,2016-10-18T13:02:14.550000-04:00
1882188,5b7c304f-8538-4050-b0d9-0f8cdfa9ae37,3T,CLOAKROOM ADVISORS LLC,401103204,LINDEN CARE LLC,2016,third_quarter,PHA,Congressional delegation outreach and education on issues related to speciality pharmacies,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,1,2016-10-18T13:09:38.417000-04:00
1882207,a8c48d5c-561b-4b89-9c6a-55ca4160c17b,Q3,CLOAKROOM ADVISORS LLC,401103204,CARD & ASSOCIATES ON BEHALF OF AMERICAN'S FOR PRESCRIPTION DRUG FAIRNESS,2016,third_quarter,PHA,Advocate for protection of 340B drug pricing program and support 340B program integrity and compliance by covered entities and pharmacies.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-10-18T13:14:53.547000-04:00
1882452,c9a7a449-0ce3-4b21-8055-b73fd0ca5f8f,Q3,"HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC",17966,ELI LILLY AND COMPANY,2016,third_quarter,PHA,Policy issues relating to prescription drug prices.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-18T13:43:12.447000-04:00
1882693,6028fe3a-0e5f-4fe2-84a1-ef66a9588189,Q3,"ALKERMES, INC.",400458235,"ALKERMES, INC.",2016,third_quarter,PHA,"Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances.  
HR 6 the 21st Century Cures Act","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,1150000,0,0,2016-10-18T14:23:51.233000-04:00
1882948,48a657be-d4f9-4043-824a-acb87dc73922,Q3,"BLUESTONE STRATEGIES, LLC",400658980,AMERICA'S HEALTH INSURANCE PLANS (AHIP),2016,third_quarter,PHA,Specialty Drugs and Prescription Drug Pricing,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-18T14:48:23.567000-04:00
1883231,086e2709-0b33-4ed4-839e-ef342eba7686,Q3,ARNOLD & PORTER KAYE SCHOLER LLP,4301,INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS,2016,third_quarter,PHA,Issues related to the regulation of pharmacy compounding.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-18T15:14:20.260000-04:00
1883266,0f41faea-12e8-471f-811a-22cf0e70e4bb,Q3,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2016,third_quarter,PHA,P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Indian Health Service,Labor, Dept of (DOL),Natl Institutes of Health (NIH),SENATE,Treasury, Dept of",,590000,0,0,2016-10-18T15:19:41.093000-04:00
1883296,57d151cb-03d7-4af5-87f7-9aeb168768fa,Q3,"BLUESTONE STRATEGIES, LLC",400658980,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2016,third_quarter,PHA,"Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-10-18T15:25:03.397000-04:00
1883306,59f6bf25-b473-4cb6-a3a2-8a4a2a293e15,Q3,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2016,third_quarter,PHA,"S. 1200/H.R. 3174 Fairness to Pet Owners Act
Veterinary Compounding Legislation
Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230
Discussions with DEA regarding use of controlled substances by veterinary practitioners","HOUSE OF REPRESENTATIVES,SENATE",,200000,0,0,2016-10-18T15:27:10.867000-04:00
1883340,adbd6d22-4a46-4dee-afa8-f3be20d338d1,Q3,COVINGTON & BURLING LLP,11195,CELGENE CORPORATION,2016,third_quarter,PHA,"Opposing the CREATES Act, S. 3056","HOUSE OF REPRESENTATIVES,SENATE",250000,,0,0,2016-10-18T15:32:35.247000-04:00
1883355,a3ecba90-6299-4506-8c1a-664aa8302f19,Q3,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,31348,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2016,third_quarter,PHA,"Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price.  Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and   medical loss ratio).

Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. 

Issues related to prescription drug abuse in Medicare.

H.R.2:  Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of  Medicare data

H.R.244:  The MAC Transparency Act

H.R.793S1190:  The Ensuring Seniors Access to Local Pharmacies Act

H.R.1021:  The Protecting the Integrity of Medicare Act

H.R.1600:  The Patient Access to Treatments Act

H.R.804:   The Access to Medicare Data Act

H.R.2298:  The Medicare Drug Abuse Prevention Act

H.R.6:  21st Century Cures Act

H.R. 1735/S.1376:  The National Defense Authorization Act - Provisions related to TRICARE pharmacy

H.R. 4062:  Protecting Seniors Access to Proper Care Act

H.R. 5951/ S.3308:  Improving Transparency and Accuracy in Medicare Part D Spending Act","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),General Services Administration (GSA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE",,643584,0,0,2016-10-18T15:33:46.187000-04:00
1883598,01cb01c1-3cb9-40a8-8126-67c0c6e7b8e7,Q3,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2016,third_quarter,PHA,Monitoring biotech legislation,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-10-18T16:17:17.613000-04:00
1884231,e54339c3-8af4-4c2d-ad83-82fb86878664,Q3,"CROSSROADS STRATEGIES, LLC",400531586,"EMD SERONO, INC.",2016,third_quarter,PHA,General pharmaceutical coverage and reimbursement issues.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-18T18:02:54.537000-04:00
1884507,77e12926-5bfa-42dd-8da4-3bd708726b9c,Q3,CAPITOL COUNSEL LLC,313715,AMERICAN HEALTH CARE ASSOCIATION,2016,third_quarter,PHA,"S.1560: Nursing Home Resident Pain Relief Act of 2011.
S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012.
S.621: Safe Prescribing Act. 
Continued monitoring of Nurse Agent and Drug disposal issue","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2016-10-18T22:07:05.550000-04:00
1884870,ea46367c-9c88-42c4-b5b0-26db67cd1581,Q3,RAMPY NORTHRUP LLC,401103289,ACADEMY OF MANAGED CARE PHARMACY,2016,third_quarter,PHA,Dissemination of pharmacoeconomic information.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-19T09:10:02.387000-04:00
1884946,72dfe6d6-bd06-4da9-bd8e-1a0462414b6b,Q3,"FLYNN & ASSOCIATES, INC.",15020,PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION,2016,third_quarter,PHA,"Medicare Part-D rebates
Trade agreements
Patent reform issues
Medicare Part-B Doctor reimbursement regulations","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-10-19T09:30:43.657000-04:00
1885002,ebac689d-1bc7-43a4-b092-c450198e07b2,Q3,"RUBICON ADVISORS, LLC",315091,TEVA PHARMACEUTICALS USA,2016,third_quarter,PHA,21st Century Cures Act,"HOUSE OF REPRESENTATIVES,SENATE",105000,,0,0,2016-10-19T09:56:29.897000-04:00
1885118,dd1342f7-0b39-415a-91f4-6b326fc267cd,3T,"RUBICON ADVISORS, LLC",315091,OFFICE OF GOVERNOR NATHAN DEAL,2016,third_quarter,PHA,"Pharmaceuticals
HR 707, Restoration of America's Wire Act","HOUSE OF REPRESENTATIVES,SENATE",43750,,0,1,2016-10-19T10:09:32.190000-04:00
1885124,e00b1fc9-fe1d-4549-8534-f36775311531,Q3,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2016,third_quarter,PHA,Pharmaceuticals,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-10-19T10:10:37.757000-04:00
1885137,91fbeea6-80f5-4059-86ab-db2017fdd42a,Q3,"RUBICON ADVISORS, LLC",315091,ALLIANCE TO PREVENT THE ABUSE OF MEDICINES,2016,third_quarter,PHA,Prescription drug abuse policy,"HOUSE OF REPRESENTATIVES,SENATE",52500,,0,0,2016-10-19T10:10:48.100000-04:00
1885141,eb095205-ac0a-4d9d-9db4-5f84bd5c0747,Q3,"RUBICON ADVISORS, LLC",315091,COLLEGE OF AMERICAN PATHOLOGISTS,2016,third_quarter,PHA,"Physician Payment Rates, Electronic Health Records Incentives program","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-10-19T10:11:54.130000-04:00
1885154,167a07ac-8ecc-450e-ba2c-393c27a80549,Q3,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2016,third_quarter,PHA,"Food and Drug Administration, Generic Drug User Fees, NHI, DEA","Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",45000,,0,0,2016-10-19T10:12:59.147000-04:00
1885446,734cf5f7-d90a-41cc-88c7-2bba973da928,Q3,THE INGRAM GROUP LLC,400577737,ELI LILLY AND COMPANY,2016,third_quarter,PHA,"S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015.
H.R.6, 21st Century Cures Act.
General issues related to the biopharmaceutical and pharmaceutical industries.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-10-19T10:45:02.753000-04:00
1885500,a738fdf2-4e25-42dd-9f55-bc78a2463b32,Q3,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2016,third_quarter,PHA,"Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,230000,0,0,2016-10-19T10:50:38.117000-04:00
1885523,48baae31-9fe3-49ce-abea-ee78ed055540,Q3,THE D MAJOR GROUP,401103162,CVS CAREMARK,2016,third_quarter,PHA,"Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act.","HOUSE OF REPRESENTATIVES,SENATE",34500,,0,0,2016-10-19T10:52:54.090000-04:00
1885584,5b737898-6d5d-4be6-baf5-1092ec5a0cc9,Q3,FORBES-TATE,400976792,PHRMA,2016,third_quarter,PHA,"Issues related to Medicare Part D; issues related to the drug industry, issues related to comparative effectiveness; issues related to follow-on biologics; issues related to the Independent Payment Advisory Board; issues related to patent reform; issues related to ASP+6 and Part B rule; issues related to PCORI; issues related to pharmaceutical drug safety track and trace program legislation; issues related to low income subsidies; issues related to the Vice President's National Cancer Moonshot Initiative.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2016-10-19T10:57:33.233000-04:00
1885816,35f3af34-1b30-484e-b075-2e9bf50fa79f,Q3,PRIME THERAPEUTICS,400339576,PRIME THERAPEUTICS,2016,third_quarter,PHA,"S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing.  S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding.  H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act.  H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016.  S.2256: Co-Prescribing Saves Lives Act of 2016.  H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability.  S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes.  S.2615: the Increasing Competition in Pharmaceuticals Act.","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2016-10-19T11:18:47.580000-04:00
1886085,81b2f2a6-4529-46b9-b907-5f216f6d8bfb,Q3,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2016,third_quarter,PHA,"Increased appropriations for systems to shorten the time between development of a drug and its release to the public
FDA reform as it relates to drug development and research         
Collaborative research on drug development                                
Human factors research related to neuropharmaceuticals
340B Drug Pricing guidelines","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)",,86662,0,0,2016-10-19T11:40:55.943000-04:00
1886353,17f9803b-b6a3-4bf8-83c2-ed7ad254b284,Q3,DENTONS US LLP,36105,PURDUE PHARMA,2016,third_quarter,PHA,U.S. and Canadian regulatory policies regarding prescription drug abuse,,,,0,0,2016-10-19T12:09:19.533000-04:00
1886538,0381ff45-a6fb-407a-a20b-75d2556ecb8b,Q3,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2016,third_quarter,PHA,Hospital discounts; 340B Program,"Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,2100000,0,0,2016-10-19T12:29:11.300000-04:00
1886692,035ef305-6586-411b-8982-ccf7572eb61c,Q3,DENTONS US LLP,36105,AMERISOURCEBERGEN,2016,third_quarter,PHA,Pharmaceutical pedigree anti-counterfeiting issues,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-10-19T12:50:41.913000-04:00